Department of Trade and Industry Secretary Cristina Roque held a series of productive meetings with top executives of global ...

The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

The broader Topix index settled 1.19 percent higher at 2,711.27. Automakers led the surge, with Honda Motor rising 1.4 percent while Toyota Motor and Subaru both gained around 3 percent.

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

TOKYO: Japan’s Nikkei share average advanced on ... approved a breast cancer treatment it is developing with AstraZeneca.

(Alliance News) - Stocks were called to open higher in London on Friday morning, although UK consumer confidence has reportedly suffered a steep fall in recent weeks.

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

Marking the second global approval after Japan, the U.S. FDA has approved Datroway (datopotamab deruxtecan), a trophoblast cell surface antigen 2-directed antibody-drug conjugate (ADC) from Daiichi ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

In Australia, the S&P/ASX 200 Index is up 0.18% at 8,325.50, recovering from losses in the previous session. Gains are led by ...